Monograph

C03CA01 - Furosemide

Propably not porphyrinogenic

Rationale

(CAVE: under revision)Sulfonamide derivative. Conflicting references, but non-metabolism as well as clinical observations point to non-porphyrinogenicity.

Chemical description

Sulfonamide derivative.

Therapeutic characteristics

Shortacting loop-diuretic.

Metabolism and pharmacokinetics

Primarily excreted by filtration and secretion as unchanged drug. Some liver metabolism may occur. The glucuronide is the most significant metabolite. Non-porphyrinogenic metabolism.

Personal communication

Thunell, patient report (n=2): tolerated. Andersson, patient report (n=9): tolerated.

Published experience

Two non-English publications seem to involve uneventful exposure of two acute porphyria patients (Lopes Montes 2004, Moeschlin 1975).

IPNet drug reports

Uneventful use reported in 47 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes C03C / C03CA or go back.

References

#	Citation details	PMID
*	Scientific articles
1.	Moeschlin S, 1975. PMID 56031.	56031
2.	2004. PMID 15219077. Lopes Montes A et al.	15219077

Citation details

PMID

Scientific articles

Moeschlin S, 1975. PMID 56031.

56031

2004. PMID 15219077.

Lopes Montes A et al.

15219077

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames